ATE313537T1 - Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden - Google Patents

Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden

Info

Publication number
ATE313537T1
ATE313537T1 AT02709746T AT02709746T ATE313537T1 AT E313537 T1 ATE313537 T1 AT E313537T1 AT 02709746 T AT02709746 T AT 02709746T AT 02709746 T AT02709746 T AT 02709746T AT E313537 T1 ATE313537 T1 AT E313537T1
Authority
AT
Austria
Prior art keywords
mcp
antagonists
activity
methods
Prior art date
Application number
AT02709746T
Other languages
English (en)
Inventor
Edgardo Laborde
Louise Robinson
Fanying Meng
Brian T Peterson
Hugo O Villar
Steven E Anuskiewicz
Yoshiro Ishiwata
Shoji Yokochi
Yukiharu Matsumoto
Takuji Kakigami
Hideaki Inagaki
Takahito Jomori
Kouji Matsushima
Original Assignee
Telik Inc
Sanwa Kagaku Kenkyusho Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc, Sanwa Kagaku Kenkyusho Co filed Critical Telik Inc
Application granted granted Critical
Publication of ATE313537T1 publication Critical patent/ATE313537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02709746T 2001-03-01 2002-02-28 Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden ATE313537T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27279201P 2001-03-01 2001-03-01
PCT/US2002/006256 WO2002070509A2 (en) 2001-03-01 2002-02-28 Antagonists of mcp-1 function and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE313537T1 true ATE313537T1 (de) 2006-01-15

Family

ID=23041292

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02709746T ATE313537T1 (de) 2001-03-01 2002-02-28 Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden

Country Status (14)

Country Link
US (2) US6809113B2 (de)
EP (1) EP1363897B1 (de)
JP (1) JP4291576B2 (de)
KR (1) KR20040018336A (de)
CN (1) CN1259315C (de)
AR (1) AR035759A1 (de)
AT (1) ATE313537T1 (de)
BR (1) BR0207750A (de)
CA (1) CA2439849A1 (de)
DE (1) DE60208159T2 (de)
ES (1) ES2254653T3 (de)
MX (1) MXPA03007861A (de)
TW (1) TWI245761B (de)
WO (1) WO2002070509A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002217999A1 (en) 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20080187508A1 (en) * 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
MX2007012082A (es) 2005-03-31 2007-11-20 Pfizer Prod Inc Derivados de ciclopentapiridina y tetrahidroquinolina.
WO2007066496A1 (en) * 2005-12-07 2007-06-14 Sumitomo Chemical Company, Limited Benzoylurea compound and use thereof
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
CA2658719A1 (en) * 2006-07-24 2008-01-31 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
WO2008071751A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
EP2481408A3 (de) 2007-03-01 2013-01-09 Probiodrug AG Neue Verwendung von Inhibitoren der Glutaminyl Cyclase
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8356920B2 (en) * 2007-12-12 2013-01-22 Levine Jonathan E Lighting device
WO2010068881A1 (en) * 2008-12-12 2010-06-17 Forest Laboratories Holdings Limited Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
EP2522341A1 (de) * 2011-05-13 2012-11-14 Tragex Pharma Pharmazeutische Zusammensetzungen mit Neuropilinhemmern und ihre Verwendung zur Vorbeugung und/oder Behandlung von angiogenen Störungen und Krebs
PT3071203T (pt) 2013-11-18 2021-03-11 Forma Therapeutics Inc Composições de tetra-hidroquinolina como inibidores de bromodomínio bet
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
EP3551034A1 (de) 2016-12-07 2019-10-16 Progenity, Inc. Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018201091A1 (en) * 2017-04-27 2018-11-01 Washington University Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
EP3643711A1 (de) 2018-10-24 2020-04-29 Bayer Animal Health GmbH Neue anthelmintische verbindungen
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
IL310679A (en) * 2021-08-11 2024-04-01 Curadev Pharma Pvt Ltd Urea history of small molecules as STING antagonists

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32700B1 (en) 1968-02-03 1973-10-31 Beecham Group Ltd Penicillins
GB1250611A (de) 1968-02-03 1971-10-20
DE2131034A1 (de) * 1971-06-23 1973-01-11 Hoechst Ag Acylharnstoffe und verfahren zu ihrer herstellung
DE2652004C3 (de) * 1976-11-15 1979-09-13 Basf Ag, 6700 Ludwigshafen l-Acyl-2-arylamino-2-imidazoline, Verfahren zu ihrer Herstellung und ihre Verwendung
US4163784A (en) 1978-03-09 1979-08-07 Pfizer Inc. Heterocyclylcarbonyl derivatives of urea, agents for dissolution of gallstones
GB8528234D0 (en) 1985-11-15 1985-12-18 Wyeth John & Brother Ltd Heterocyclic compounds
JP2650055B2 (ja) 1988-11-28 1997-09-03 キヤノン株式会社 電子写真感光体
FR2672888B1 (fr) 1991-02-14 1994-02-04 Fabre Medicament Pierre Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
AU1208397A (en) 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
JPH09255572A (ja) 1996-03-26 1997-09-30 Takeda Chem Ind Ltd ケモカイン受容体拮抗剤
US6686353B1 (en) 1996-05-20 2004-02-03 Teijin Intellectual Property Center Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
US6281212B1 (en) 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998004554A1 (en) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
EP0927167A1 (de) 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenylbenzimidazol-derivate als mcp-1 antagonisten
AU5812498A (en) 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
JP2002502844A (ja) 1998-02-03 2002-01-29 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用
EP1101759A4 (de) * 1998-07-31 2001-12-12 Nippon Soda Co Phenylazol-derivate, verfahren zu ihrer herstellung und medikamente für hyperlipemie
US6316449B1 (en) * 1999-07-08 2001-11-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists
EP1255741A2 (de) 2000-02-01 2002-11-13 Cor Therapeutics, Inc. 2-(1h)-chinolinone und 2-(1h)-chinoxalinone inhibitoren von xa faktor
WO2001057044A1 (en) 2000-02-01 2001-08-09 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
EP1255743A1 (de) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-dihydro-2h-benzo[1,4]oxazine als faktor xa inhibitoren

Also Published As

Publication number Publication date
KR20040018336A (ko) 2004-03-03
US20030105085A1 (en) 2003-06-05
WO2002070509A8 (en) 2003-11-06
JP2004527503A (ja) 2004-09-09
TWI245761B (en) 2005-12-21
US6809113B2 (en) 2004-10-26
CN1494539A (zh) 2004-05-05
CN1259315C (zh) 2006-06-14
EP1363897A2 (de) 2003-11-26
CA2439849A1 (en) 2002-09-12
WO2002070509A3 (en) 2003-05-30
US7297696B2 (en) 2007-11-20
AR035759A1 (es) 2004-07-07
EP1363897B1 (de) 2005-12-21
DE60208159D1 (de) 2006-01-26
US20050054668A1 (en) 2005-03-10
JP4291576B2 (ja) 2009-07-08
ES2254653T3 (es) 2006-06-16
WO2002070509A2 (en) 2002-09-12
DE60208159T2 (de) 2006-08-17
HK1060728A1 (en) 2004-08-20
BR0207750A (pt) 2004-03-23
MXPA03007861A (es) 2004-10-15

Similar Documents

Publication Publication Date Title
DE60208159D1 (de) Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE340789T1 (de) Antagonisten der mcp-1-funktion und verfahren zu deren verwendung
DE60230868D1 (de) Criptoblockierende antikörper und deren verwendung
DE60239485D1 (de) Benzamid und heteroarylamid als p2x7-rezeptorantagonisten
DE60227300D1 (de) Strukturen von anschlusselementen und anzuschliessende komponente
ATE305468T1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ID30401A (id) Turunan-turunan indol dan penggunaannya sebagai antagonis mcp-1
ATE458717T1 (de) Beta-amino-alpha-cyanoacrylate und deren verwendung als herbizide
DE60104776D1 (de) Diphenylharnstoffderivate und deren Verwendung als alpha2/5-HT2c Antagonisten
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
EP1581622A4 (de) Remodellierung und glycokonjugation von erythropoetin
DE60224194D1 (de) Arzneizusammensetzungen enthaltend terbinafin und deren verwendung
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DK1558595T3 (da) Piperazinyl- og diazapanylbenzamider og -benzthioamider
ATE364575T1 (de) Zeolithe und deren verwendung
DE60230245D1 (de) Wabenkonstruktion und deren zusammenbau
DE69903961D1 (de) Muscarinagonisten und antagonisten
ITMI20021247A1 (it) Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
DE60302107D1 (de) Saure Öl-in-Wasser emulgierte Zusammensetzungen und deren Verwendung
DE69915113D1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
DE60238174D1 (de) Fluoropolymere und Herstellungs- und Verwendungsverfahren
DE60125374D1 (de) Bisacrylamid enthaltende dentalmassen und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1363897

Country of ref document: EP

REN Ceased due to non-payment of the annual fee